First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun Vasant Balar, Joaquim Bellmunt, Jacqueline Vuky et al.|The Lancet Oncology|2017Cited by 1.3k
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial CancerJacqueline Vuky, Elizabeth R. Plimack, Arjun Vasant Balar et al.|Journal of Clinical Oncology|2020Cited by 292